AAPL297.49+3.19 (+1.08%) ▲|ABBV234.67-0.10 (-0.04%) ▼|ABT91.05+0.52 (+0.57%) ▲|ACN129.20+2.19 (+1.72%) ▲|ADBE198.64+1.21 (+0.61%) ▲|AMAT588.23+2.35 (+0.40%) ▲|AMD518.61-1.24 (-0.24%) ▼|AMGN351.39+4.38 (+1.26%) ▲|AMT175.05-4.33 (-2.41%) ▼|AMZN239.89+5.78 (+2.47%) ▲|AVGO384.07+3.92 (+1.03%) ▲|AXP342.76+4.98 (+1.47%) ▲|BA220.97+4.26 (+1.97%) ▲|BAC57.53-0.39 (-0.66%) ▼|BKNG182.11+13.17 (+7.80%) ▲|BLK982.52-32.81 (-3.23%) ▼|BMY55.09-0.44 (-0.79%) ▼|BNY145.28-2.01 (-1.36%) ▼|BRK-B497.07+4.26 (+0.86%) ▲|C143.40-1.57 (-1.08%) ▼|CAT1,000.35+16.11 (+1.64%) ▲|CL92.99+1.56 (+1.71%) ▲|CMCSA22.59-0.22 (-0.94%) ▼|COF201.81+4.00 (+2.02%) ▲|COP106.94-3.04 (-2.76%) ▼|COST961.11+3.43 (+0.36%) ▲|CRM154.33+0.91 (+0.59%) ▲|CSCO120.51-0.64 (-0.53%) ▼|CVS101.46-0.12 (-0.11%) ▼|CVX171.56-4.42 (-2.51%) ▼|DE609.73+17.79 (+3.01%) ▲|DHR187.97+9.00 (+5.03%) ▲|DIS102.29-1.24 (-1.20%) ▼|DUK125.18+0.13 (+0.10%) ▲|EMR142.20-0.94 (-0.66%) ▼|FDX313.03-4.21 (-1.33%) ▼|GD346.28-4.06 (-1.16%) ▼|GE367.55+11.08 (+3.11%) ▲|GEV1,063.92+28.94 (+2.80%) ▲|GILD125.47+0.42 (+0.34%) ▲|GM79.81+0.86 (+1.09%) ▲|GOOG347.89+1.81 (+0.52%) ▲|GOOGL348.75+2.66 (+0.77%) ▲|GS1,081.98-12.46 (-1.14%) ▼|HD340.26+15.81 (+4.87%) ▲|HON227.06+4.69 (+2.11%) ▲|IBM262.50-2.44 (-0.92%) ▼|INTC132.90+0.62 (+0.47%) ▲|INTU268.42+10.37 (+4.02%) ▲|ISRG401.83-1.35 (-0.33%) ▼|JNJ240.48+1.40 (+0.59%) ▲|JPM333.09-1.06 (-0.32%) ▼|KO81.24+0.93 (+1.15%) ▲|LIN521.77+9.51 (+1.86%) ▲|LLY1,109.80+2.72 (+0.25%) ▲|LMT493.50-10.17 (-2.02%) ▼|LOW220.88+7.34 (+3.44%) ▲|LRCX368.81-2.52 (-0.68%) ▼|MA493.69+5.62 (+1.15%) ▲|MCD274.21+2.55 (+0.94%) ▲|MDLZ62.15+1.09 (+1.79%) ▲|MDT80.65+0.02 (+0.02%) ▲|META560.77-1.43 (-0.25%) ▼|MMM167.73+5.89 (+3.64%) ▲|MO72.05+0.44 (+0.61%) ▲|MRK120.85+1.25 (+1.04%) ▲|MS221.35-4.69 (-2.07%) ▼|MSFT372.37-1.58 (-0.42%) ▼|MU1,037.63-14.15 (-1.34%) ▼|NEE86.79+0.36 (+0.41%) ▲|NFLX71.73-1.10 (-1.50%) ▼|NKE41.99-0.40 (-0.93%) ▼|NOW94.53-1.41 (-1.47%) ▼|NVDA199.69-0.32 (-0.16%) ▼|ORCL157.45-7.71 (-4.67%) ▼|PEP143.17+1.12 (+0.79%) ▲|PFE24.15-0.58 (-2.33%) ▼|PG153.09+2.23 (+1.47%) ▲|PLTR113.22-3.48 (-2.98%) ▼|PM178.59-0.10 (-0.06%) ▼|QCOM196.22-7.92 (-3.88%) ▼|RTX185.84-0.55 (-0.30%) ▼|SBUX103.92+2.87 (+2.84%) ▲|SCHW91.38-1.79 (-1.92%) ▼|SO94.74-0.20 (-0.21%) ▼|SPG218.90+2.16 (+1.00%) ▲|T22.41-0.41 (-1.78%) ▼|TMO489.11+19.76 (+4.21%) ▲|TMUS182.76-1.81 (-0.98%) ▼|TSLA378.32-3.29 (-0.86%) ▼|TXN303.86-0.50 (-0.16%) ▼|UBER74.45+4.78 (+6.86%) ▲|UNH406.37-2.89 (-0.70%) ▼|UNP260.55+1.94 (+0.75%) ▲|UPS105.24-0.59 (-0.56%) ▼|USB60.02-0.03 (-0.05%) ▼|V331.70+3.22 (+0.98%) ▲|VZ45.58-1.16 (-2.47%) ▼|WFC83.89-0.24 (-0.29%) ▼|WMT119.52+0.10 (+0.08%) ▲|XOM136.44-3.29 (-2.35%) ▼|AAPL297.49+3.19 (+1.08%) ▲|ABBV234.67-0.10 (-0.04%) ▼|ABT91.05+0.52 (+0.57%) ▲|ACN129.20+2.19 (+1.72%) ▲|ADBE198.64+1.21 (+0.61%) ▲|AMAT588.23+2.35 (+0.40%) ▲|AMD518.61-1.24 (-0.24%) ▼|AMGN351.39+4.38 (+1.26%) ▲|AMT175.05-4.33 (-2.41%) ▼|AMZN239.89+5.78 (+2.47%) ▲|AVGO384.07+3.92 (+1.03%) ▲|AXP342.76+4.98 (+1.47%) ▲|BA220.97+4.26 (+1.97%) ▲|BAC57.53-0.39 (-0.66%) ▼|BKNG182.11+13.17 (+7.80%) ▲|BLK982.52-32.81 (-3.23%) ▼|BMY55.09-0.44 (-0.79%) ▼|BNY145.28-2.01 (-1.36%) ▼|BRK-B497.07+4.26 (+0.86%) ▲|C143.40-1.57 (-1.08%) ▼|CAT1,000.35+16.11 (+1.64%) ▲|CL92.99+1.56 (+1.71%) ▲|CMCSA22.59-0.22 (-0.94%) ▼|COF201.81+4.00 (+2.02%) ▲|COP106.94-3.04 (-2.76%) ▼|COST961.11+3.43 (+0.36%) ▲|CRM154.33+0.91 (+0.59%) ▲|CSCO120.51-0.64 (-0.53%) ▼|CVS101.46-0.12 (-0.11%) ▼|CVX171.56-4.42 (-2.51%) ▼|DE609.73+17.79 (+3.01%) ▲|DHR187.97+9.00 (+5.03%) ▲|DIS102.29-1.24 (-1.20%) ▼|DUK125.18+0.13 (+0.10%) ▲|EMR142.20-0.94 (-0.66%) ▼|FDX313.03-4.21 (-1.33%) ▼|GD346.28-4.06 (-1.16%) ▼|GE367.55+11.08 (+3.11%) ▲|GEV1,063.92+28.94 (+2.80%) ▲|GILD125.47+0.42 (+0.34%) ▲|GM79.81+0.86 (+1.09%) ▲|GOOG347.89+1.81 (+0.52%) ▲|GOOGL348.75+2.66 (+0.77%) ▲|GS1,081.98-12.46 (-1.14%) ▼|HD340.26+15.81 (+4.87%) ▲|HON227.06+4.69 (+2.11%) ▲|IBM262.50-2.44 (-0.92%) ▼|INTC132.90+0.62 (+0.47%) ▲|INTU268.42+10.37 (+4.02%) ▲|ISRG401.83-1.35 (-0.33%) ▼|JNJ240.48+1.40 (+0.59%) ▲|JPM333.09-1.06 (-0.32%) ▼|KO81.24+0.93 (+1.15%) ▲|LIN521.77+9.51 (+1.86%) ▲|LLY1,109.80+2.72 (+0.25%) ▲|LMT493.50-10.17 (-2.02%) ▼|LOW220.88+7.34 (+3.44%) ▲|LRCX368.81-2.52 (-0.68%) ▼|MA493.69+5.62 (+1.15%) ▲|MCD274.21+2.55 (+0.94%) ▲|MDLZ62.15+1.09 (+1.79%) ▲|MDT80.65+0.02 (+0.02%) ▲|META560.77-1.43 (-0.25%) ▼|MMM167.73+5.89 (+3.64%) ▲|MO72.05+0.44 (+0.61%) ▲|MRK120.85+1.25 (+1.04%) ▲|MS221.35-4.69 (-2.07%) ▼|MSFT372.37-1.58 (-0.42%) ▼|MU1,037.63-14.15 (-1.34%) ▼|NEE86.79+0.36 (+0.41%) ▲|NFLX71.73-1.10 (-1.50%) ▼|NKE41.99-0.40 (-0.93%) ▼|NOW94.53-1.41 (-1.47%) ▼|NVDA199.69-0.32 (-0.16%) ▼|ORCL157.45-7.71 (-4.67%) ▼|PEP143.17+1.12 (+0.79%) ▲|PFE24.15-0.58 (-2.33%) ▼|PG153.09+2.23 (+1.47%) ▲|PLTR113.22-3.48 (-2.98%) ▼|PM178.59-0.10 (-0.06%) ▼|QCOM196.22-7.92 (-3.88%) ▼|RTX185.84-0.55 (-0.30%) ▼|SBUX103.92+2.87 (+2.84%) ▲|SCHW91.38-1.79 (-1.92%) ▼|SO94.74-0.20 (-0.21%) ▼|SPG218.90+2.16 (+1.00%) ▲|T22.41-0.41 (-1.78%) ▼|TMO489.11+19.76 (+4.21%) ▲|TMUS182.76-1.81 (-0.98%) ▼|TSLA378.32-3.29 (-0.86%) ▼|TXN303.86-0.50 (-0.16%) ▼|UBER74.45+4.78 (+6.86%) ▲|UNH406.37-2.89 (-0.70%) ▼|UNP260.55+1.94 (+0.75%) ▲|UPS105.24-0.59 (-0.56%) ▼|USB60.02-0.03 (-0.05%) ▼|V331.70+3.22 (+0.98%) ▲|VZ45.58-1.16 (-2.47%) ▼|WFC83.89-0.24 (-0.29%) ▼|WMT119.52+0.10 (+0.08%) ▲|XOM136.44-3.29 (-2.35%) ▼|
24.7 C
New York
Wednesday, June 24, 2026

Tag: biopharmaceutical company

newssourceFORcompanyinformationcontent1marketreleases

Rakovina Therapeutics KT-5000AI Program Yields Potent ATR Inhibitor Hits in Early Screening

Compounds developed through collaboration with Variational AI show targeted activity 
Compounds developed through collaboration with Variational AI show targeted activity

Ipsen announces changes to its Executive Committee

PARIS, FRANCE, 23 July 2025 - Ipsen (Euronext: IPN; ADR: IPSEY), a global specialty care biopharmaceutical company, today announced the following changes to its Executive Committee:

Pharvaris Announces Pricing of Upsized $175 Million Public Offering of Ordinary Shares and Pre-Funded Warrants

ZUG, Switzerland, July 22, 2025 (GLOBE NEWSWIRE) -- Pharvaris N.V. (“Pharvaris,” Nasdaq: PHVS), a late-stage biopharmaceutical company developing novel, oral bradykinin B2 receptor antagonists to address unmet needs of those living with bradykinin-mediated diseases such as hereditary angioedema (HAE) and acquired angioedema due to C1 inhibitor deficiency (AAE-C1INH), announced today the pricing of an underwritten offering of (i) 8,250,000 of its ordinary shares at a price of $20.00 per share and (ii) to one investor, pre-funded warrants to purchase 500,000 ordinary shares at a price of $19.99 per pre-funded warrant, which represents the per share public offering price for the ordinary shares less the $0.01 per share exercise price for each such pre-funded warrant. All shares and pre-funded warrants in the offering are to be sold by Pharvaris. In addition, Pharvaris has granted the underwriters a 30-day option to purchase up to an additional 1,312,500 ordinary shares at the public offering price, less underwriting discounts and commissions. The gross proceeds to Pharvaris from the offering, before deducting underwriting discounts and commissions and offering expenses, are expected to be approximately $175 million, excluding any exercise of the underwriters’ option to purchase additional shares. The offering is expected to close on or about July 24, 2025, subject to satisfaction of customary closing conditions.

Supernus Pharmaceuticals to Announce Second Quarter 2025 Financial Results and Host Conference Call and Webcast on August 5, 2025

ROCKVILLE, Md., July 22, 2025 (GLOBE NEWSWIRE) -- Supernus Pharmaceuticals, Inc. (Nasdaq: SUPN), a biopharmaceutical company focused on developing and commercializing products for the treatment of central nervous system (CNS) diseases, today announced that the Company expects to report financial and business results for the second quarter of 2025 after the market closes on Tuesday, August 5, 2025.

Rhythm Pharmaceuticals to Report Second Quarter 2025 Financial Results on Tuesday, August 5, 2025

BOSTON, July 22, 2025 (GLOBE NEWSWIRE) -- Rhythm Pharmaceuticals, Inc. (Nasdaq: RYTM), a global commercial-stage biopharmaceutical company focused on transforming the lives of patients living with rare neuroendocrine diseases, today announced that it will host a live conference call and webcast at 8:00 a.m. ET on Tuesday, August 5, 2025 to report its second quarter 2025 financial results and provide a corporate update.

Liminatus Pharma, Inc. Initiates Strategic Review of Blockchain-Integrated Treasury Strategy

Liminatus Pharma reviews digital asset treasury strategies to enhance capital efficiency.

Coeptis (COEP) Extinguishes Convertible Note with YA II PN, Ltd

WEXFORD, Pa., July 22, 2025 (GLOBE NEWSWIRE) -- Coeptis Therapeutics Holdings, Inc. (Nasdaq: COEP) (“Coeptis” or the “Company”), a next-gen technology and biopharmaceutical company, is pleased to announce the extinguishment of its convertible note with YA II PN, Ltd (“Yorkville”).  

Halozyme to Report Second Quarter 2025 Financial and Operating Results

SAN DIEGO, July 22, 2025 /PRNewswire/ -- Halozyme Therapeutics, Inc. (NASDAQ: HALO) ("Halozyme") today announced it will release its second quarter 2025 financial and...

Telix Reports $204M Revenue, Up 63% YOY

MELBOURNE, Australia and INDIANAPOLIS, July 22, 2025 (GLOBE NEWSWIRE) -- Telix Pharmaceuticals Limited (ASX: TLX, NASDAQ: TLX, “Telix”) today provides an update on its commercial and operational performance for the quarter ended 30 June 2025 (Q2 2025). All figures are in USD unless stated otherwise.

Avadel Announces Grant of Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)

DUBLIN, July 21, 2025 (GLOBE NEWSWIRE) -- Avadel Pharmaceuticals plc (Nasdaq: AVDL), a company focused on transforming medicines to transform lives, today announced that the Compensation Committee of Avadel’s Board of Directors approved the grant of non-statutory options to six (6) new employees to purchase 34,200 ordinary shares under Avadel’s 2021 Inducement Plan. The awards were granted as an inducement material to the employee’s acceptance of employment with Avadel in accordance with Nasdaq Listing Rule 5635(c)(4). The options have a ten-year term and vest over four years, with 25% vesting on the one-year anniversary of each new employee’s respective start date and 25% vesting on the second, third, and fourth anniversary thereafter. The options are subject to the terms and conditions of Avadel’s 2021 Inducement Plan approved by the Board of Directors in November 2021 and the terms and conditions of award agreements covering the grants.

UPDATE – Daré Bioscience to Host August 6 Webinar: The DARE to PLAY™ Difference – The Sildenafil Cream That Raises the Bar

A first-of-its-kind solution for women’s arousal - the same active ingredient as in Viagra® for men - in a proprietary topical formulation demonstrated to work where women need it most

Update On Clinical Trial Milestone – CytoMed Therapeutics Achieves Completion of Dose Level 1 of its ANGELICA TRIAL, and Proceeding to Dose Level 2...

SINGAPORE, July 21, 2025 (GLOBE NEWSWIRE) -- Further to our announcement filed on Form 6-K on November 20, 2024, CytoMed Therapeutics Limited (NASDAQ: GDTC) (“CytoMed” or “Company”), a Singapore-based clinical stage biopharmaceutical company focused on harnessing its proprietary technologies to develop novel donor blood-derived, cell-based allogeneic therapies for the affordable treatment of blood and solid cancers, is pleased to announce the successful completion of dose level 1 for its first-in-human Phase I dose-escalation clinical trial (NCT05302037) (“ANGELICA Trial”) for four late stage cancer patients and is scheduled to start dose level 2 of the ANGELICA Trial in third quarter of 2025.

Alkermes Announces Positive Topline Results From Vibrance-1 Phase 2 Study of Once-Daily Alixorexton in Patients With Narcolepsy Type 1

– Alixorexton Demonstrated Clinically Meaningful and Statistically Significant Improvements in Wakefulness at All Doses Tested Compared to Placebo in Patients With Narcolepsy Type 1 – –...

Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against Hims & Hers and Sarepta and Encourages Investors to...

Bragar Eagel & Squire, P.C. Litigation Partner Brandon Walker Encourages Investors Who Suffered Losses In Hims & Hers (HIMS) or Sarepta (SRPT) To Contact Him Directly To Discuss Their Options

- A word from our sponsors -

spot_img

Newsletter Signup

Name(Required)
Email(Required)
Privacy(Required)
This field is for validation purposes and should be left unchanged.
HomeTagsBiopharmaceutical company

Explore

Press Releases

News & Opinion

Living

Others

Follow us

© Copyright 2025. BusinessPressWire® / 14 Wall Street New York City NY 10005 +1 888-502-0266 / Disclaimers